ω3 polyunsaturated fatty acids as immunomodulators in colorectal cancer: New potential role in adjuvant therapies

Frontiers in Immunology

Volumn 7, Issue NOV, 2016, Pages

  Miccadei, Stefania ^a   Masella, Roberta ^b   Mileo, Anna Maria ^a   Gessani, Sandra ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adjuvant therapy; Colorectal cancer; Immunomodulation; Inflammation; 3 polyunsaturated fatty acids

Indexed keywords

OMEGA 3 FATTY ACID;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL GROWTH; CELL PROLIFERATION; CELL SIGNALING ASSAY; COLORECTAL CANCER; DIET SUPPLEMENTATION; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; LIPID METABOLISM; MEDITERRANEAN DIET; PROSPECTIVE STUDY; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 85006109823     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00486     Document Type: Short Survey

References (83)

1. Pietrzyk L, Torres A, Maciejewski R, Torres K. Obesity and obese-related chronic low-grade inflammation in promotion of colorectal cancer development. Asian Pac J Cancer Prev (2015) 16(10):4161-8. doi:10.7314/APJCP.2015.16.10.4161
2. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: a review. Updates Surg (2016) 68(1):7-11. doi:10.1007/s13304-016-0359-y
3. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 30(7):1073-81. doi:10.1093/carcin/bgp127
4. Morrison DS, Parr CL, Lam TH, Ueshima H, Kim HC, Jee SH, et al. Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration. Asian Pac J Cancer Prev (2013) 14(2):1083-7. doi:10.7314/APJCP.2013.14.2.1083
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140(6):883-99. doi:10.1016/j.cell.2010.01.025
6. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother (2013) 62(3):405-10. doi:10.1007/s00262-012-1390-6
7. Turati F, Edefonti V, Bravi F, Ferraroni M, Talamini R, Giacosa A, et al. Adherence to the European food safety authority's dietary recommendations and colorectal cancer risk. Eur J Clin Nutr (2012) 66(4):517-22. doi:10.1038/ejcn.2011.217
8. Wiktorowska-Owczarek A, Berezinska M, Nowak JZ. PUFAs: structures, metabolism and functions. Adv Clin Exp Med (2015) 24(6):931-41. doi:10.17219/acem/31243
9. Ferreri C, Chatgilialoglu C. Membrane Lipidomics for Personalized Health. Chichester: Wiley & Sons Ltd. (2015).
10. Das UN. Essential fatty acids-a review. Curr Pharm Biotechnol (2006) 7(6):467-82. doi:10.2174/138920106779116856
11. Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br J Nutr (2008) 100(6):1152-7. doi:10.1017/S0007114508992576
12. Akhtar Khan N. Polyunsaturated fatty acids in the modulation of T-cell signalling. Prostaglandins Leukot Essent Fatty Acids (2010) 82(4-6):179-87. doi:10.1016/j.plefa.2010.02.023
13. Casas R, Sacanella E, Estruch R. The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocr Metab Immune Disord Drug Targets (2014) 14(4):245-54. doi:10.2174/1871530314666140922153350
14. Benetou V, Trichopoulou A, Orfanos P, Naska A, Lagiou P, Boffetta P, et al. Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort. Br J Cancer (2008) 99(1):191-5. doi:10.1038/sj.bjc.6604418
15. Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fito M, Escoda R, et al. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. Am J Clin Nutr (2009) 89(1):248-56. doi:10.3945/ajcn.2008.26094
16. Qi K, Hall M, Deckelbaum RJ. Long-chain polyunsaturated fatty acid accretion in brain. Curr Opin Clin Nutr Metab Care (2002) 5(2):133-8. doi:10.1097/00075197-200203000-00003
17. Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors (2009) 35(3):266-72. doi:10.1002/biof.42
18. Geelen A, Schouten JM, Kamphuis C, Stam BE, Burema J, Renkema JM, et al. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am J Epidemiol (2007) 166(10):1116-25. doi:10.1093/aje/kwm197
19. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol (2011) 58(20):2047-67. doi:10.1016/j.jacc.2011.06.063
20. Wang S, Xie J, Li H, Yang K. Differences of polyunsaturated fatty acid in patients with colorectal cancer and healthy people. J Cancer Res Ther (2015) 11(2):459-63. doi:10.4103/0973-1482.147702
21. Yang K, Li H, Dong J, Dong Y, Wang CZ. Expression profile of polyunsaturated fatty acids in colorectal cancer. World J Gastroenterol (2015) 21(8):2405-12. doi:10.3748/wjg.v21.i8.2405
22. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) (2008) 233(6):674-88. doi:10.3181/0711-MR-311
23. D'Archivio M, Scazzocchio B, Giammarioli S, Fiani ML, Vari R, Santangelo C, et al. omega3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS One (2013) 8(10):e77432. doi:10.1371/journal.pone.0077432
24. Giuliani A, Ferrara F, Scimo M, Angelico F, Olivieri L, Basso L. Adipose tissue fatty acid composition and colon cancer: a case-control study. Eur J Nutr (2014) 53(4):1029-37. doi:10.1007/s00394-013-0605-8
25. Hall MN, Chavarro JE, Lee IM, Willett WC, Ma J. A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev (2008) 17(5):1136-43. doi:10.1158/1055-9965.EPI-07-2803
26. Mocellin MC, Camargo CQ, Nunes EA, Fiates GM, Trindade EB. A systematic review and meta-analysis of the n-3 polyunsaturated fatty acids effects on inflammatory markers in colorectal cancer. Clin Nutr (2016) 35(2):359-69. doi:10.1016/j.clnu.2015.04.013
27. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr (2012) 107(Suppl 2):S228-39. doi:10.1017/S0007114512001614
28. Serini S, Ottes Vasconcelos R, Fasano E, Calviello G. How plausible is the use of dietary n-3 PUFA in the adjuvant therapy of cancer? Nutr Res Rev (2016) 29(1):102-25. doi:10.1017/S0954422416000044
29. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut (2012) 61(1):135-49. doi:10.1136/gut.2010.233718
30. Serini S, Ottes Vasconcelos R, Fasano E, Calviello G. Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer. Expert Opin Ther Targets (2016) 20(7):843-58. doi:10.1517/14728222.2016.1139085
31. Cheshmehkani A, Senatorov IS, Kandi P, Singh M, Britt A, Hayslett R, et al. Fish oil and flax seed oil supplemented diets increase FFAR4 expression in the rat colon. Inflamm Res (2015) 64(10):809-15. doi:10.1007/s00011-015-0864-3
32. Robbins GT, Nie D. PPAR gamma, bioactive lipids, and cancer progression. Front Biosci (Landmark Ed) (2012) 17:1816-34. doi:10.2741/4021
33. Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. J Nutr Biochem (2012) 23(2):101-5. doi:10.1016/j.jnutbio.2011.07.001
34. Snodgrass RG, Huang S, Choi IW, Rutledge JC, Hwang DH. Inflammasome-mediated secretion of IL-1beta in human monocytes through TLR2 activation; modulation by dietary fatty acids. J Immunol (2013) 191(8):4337-47. doi:10.4049/jimmunol.1300298
35. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity (2013) 38(6):1154-63. doi:10.1016/j.immuni.2013.05.015
36. Williams-Bey Y, Boularan C, Vural A, Huang NN, Hwang IY, Shan-Shi C, et al. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy. PLoS One (2014) 9(6):e97957. doi:10.1371/journal.pone.0097957
37. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 142(5):687-98. doi:10.1016/j.cell.2010.07.041
38. Monk JM, Liddle DM, De Boer AA, Brown MJ, Power KA, Ma DW, et al. Fish-oil-derived n-3 PUFAs reduce inflammatory and chemotactic adipokine-mediated cross-talk between co-cultured murine splenic CD8+ T cells and adipocytes. J Nutr (2015) 145(4):829-38. doi:10.3945/jn.114.205443
39. Li S, Sun Y, Liang CP, Thorp EB, Han S, Jehle AW, et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res (2009) 105(11):1072-82. doi:10.1161/CIRCRESAHA.109.199570
40. Chang HY, Lee HN, Kim W, Surh YJ. Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor gamma activation. Life Sci (2015) 120:39-47. doi:10.1016/j.lfs.2014.10.014
41. Titos E, Rius B, Gonzalez-Periz A, Lopez-Vicario C, Moran-Salvador E, Martinez-Clemente M, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol (2011) 187(10):5408-18. doi:10.4049/jimmunol.1100225
42. De Boer AA, Monk JM, Robinson LE. Docosahexaenoic acid decreases pro-inflammatory mediators in an in vitro murine adipocyte macrophage co-culture model. PLoS One (2014) 9(1):e85037. doi:10.1371/journal.pone.0085037
43. Mizota T, Fujita-Kambara C, Matsuya N, Hamasaki S, Fukudome T, Goto H, et al. Effect of dietary fatty acid composition on Th1/Th2 polarization in lymphocytes. JPEN J Parenter Enteral Nutr (2009) 33(4):390-6. doi:10.1177/0148607108325252
44. Yessoufou A, Ple A, Moutairou K, Hichami A, Khan NA. Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. J Lipid Res (2009) 50(12):2377-88. doi:10.1194/jlr.M900101-JLR200
45. Kong W, Yen JH, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun (2011) 25(5):872-82. doi:10.1016/j.bbi.2010.09.012
46. Berger H, Vegran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, et al. SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res (2013) 73(12):3578-90. doi:10.1158/0008-5472.CAN-12-4018
47. Monk JM, Hou TY, Turk HF, McMurray DN, Chapkin RS. n3 PUFAs reduce mouse CD4+ T-cell ex vivo polarization into Th17 cells. J Nutr (2013) 143(9):1501-8. doi:10.3945/jn.113.178178
48. Teague H, Rockett BD, Harris M, Brown DA, Shaikh SR. Dendritic cell activation, phagocytosis and CD69 expression on cognate T cells are suppressed by n-3 long-chain polyunsaturated fatty acids. Immunology (2013) 139(3):386-94. doi:10.1111/imm.12088
49. Carlsson JA, Wold AE, Sandberg AS, Ostman SM. The polyunsaturated fatty acids arachidonic acid and docosahexaenoic acid induce mouse dendritic cells maturation but reduce T-cell responses in vitro. PLoS One (2015) 10(11):e0143741. doi:10.1371/journal.pone.0143741
50. Han SC, Koo DH, Kang NJ, Yoon WJ, Kang GJ, Kang HK, et al. Docosahexaenoic acid alleviates atopic dermatitis by generating tregs and IL-10/TGF-beta-modified macrophages via a TGF-beta-dependent mechanism. J Invest Dermatol (2015) 135(6):1556-64. doi:10.1038/jid.2014.488
51. Lian M, Luo W, Sui Y, Li Z, Hua J. Dietary n-3 PUFA protects mice from con a induced liver injury by modulating regulatory T cells and PPAR-gamma expression. PLoS One (2015) 10(7):e0132741. doi:10.1371/journal.pone.0132741
52. Lee JY, Zhao L, Hwang DH. Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev (2010) 68(1):38-61. doi:10.1111/j.1753-4887.2009.00259.x
53. Tuncer S, Banerjee S. Eicosanoid pathway in colorectal cancer: recent updates. World J Gastroenterol (2015) 21(41):11748-66. doi:10.3748/wjg.v21.i41.11748
54. Roy J, Le Guennec JY, Galano JM, Thireau J, Bultel-Ponce V, Demion M, et al. Non-enzymatic cyclic oxygenated metabolites of omega-3 polyunsaturated fatty acid: bioactive drugs? Biochimie (2016) 120:56-61. doi:10.1016/j.biochi.2015.06.010
55. Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer (2006) 119(10):2247-54. doi:10.1002/ijc.22153
56. Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and-2 and HIF-1alpha induction pathway. Carcinogenesis (2004) 25(12):2303-10. doi:10.1093/carcin/bgh265
57. Habbel P, Weylandt KH, Lichopoj K, Nowak J, Purschke M, Wang JD, et al. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. World J Gastroenterol (2009) 15(9):1079-84. doi:10.3748/wjg.15.1079
58. Dupertuis YM, Meguid MM, Pichard C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care (2007) 10(4):427-32. doi:10.1097/MCO.0b013e3281e2c9d4
59. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat (2004) 73(3-4):155-72. doi:10.1016/j.prostaglandins.2004.03.005
60. Poorani R, Bhatt AN, Dwarakanath BS, Das UN. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur J Pharmacol (2016) 785:116-32. doi:10.1016/j.ejphar.2015.08.049
61. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal-cancer in women. N Engl J Med (1995) 333(10):609-14. doi:10.1056/Nejm199509073331001
62. Fluckiger A, Dumont A, Derangere V, Rebe C, de Rosny C, Causse S, et al. Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFalpha. Oncogene (2016) 35(35):4611-22. doi:10.1038/onc.2015.523
63. Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR. A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas. Exp Biol Med (Maywood) (2012) 237(12):1387-93. doi:10.1258/ebm.2012.012244
64. Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR. Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation. Exp Biol Med (Maywood) (2014) 239(3):302-10. doi:10.1177/1535370213514927
65. Tsoukas MA, Ko BJ, Witte TR, Dincer F, Hardman WE, Mantzoros CS. Dietary walnut suppression of colorectal cancer in mice: mediation by miRNA patterns and fatty acid incorporation. J Nutr Biochem (2015) 26(7):776-83. doi:10.1016/j.jnutbio.2015.02.009
66. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev (2011) 30(3-4):507-23. doi:10.1007/s10555-011-9311-2
67. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet (2003) 362(9399):1921-8. doi:10.1016/S0140-6736(03)14966-5
68. Calder PC. n-3 fatty acids, inflammation, and immunity-relevance to postsurgical and critically ill patients. Lipids (2004) 39(12):1147-61. doi:10.1007/s11745-004-1342-z
69. Sorensen LS, Thorlacius-Ussing O, Schmidt EB, Rasmussen HH, Lundbye-Christensen S, Calder PC, et al. Randomized clinical trial of perioperative omega-3 fatty acid supplements in elective colorectal cancer surgery. Br J Surg (2014) 101(2):33-42. doi:10.1002/bjs.9361
70. Senkal M, Haaker R, Linseisen J, Wolfram G, Homann HH, Stehle P. Preoperative oral supplementation with long-chain omega-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue. JPEN J Parenter Enteral Nutr (2005) 29(4):236-40. doi:10.1177/0148607105029004236
71. Sorensen LS, Rasmussen HH, Aardestrup IV, Thorlacius-Ussing O, Lindorff-Larsen K, Schmidt EB, et al. Rapid incorporation of omega-3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. JPEN J Parenter Enteral Nutr (2014) 38(5):617-24. doi:10.1177/0148607113491782
72. Sorensen LS, Thorlacius-Ussing O, Rasmussen HH, Lundbye-Christensen S, Calder PC, Lindorff-Larsen K, et al. Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B(4) and leukotriene B(5) production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. Nutrients (2014) 6(10):4043-57. doi:10.3390/nu6104043
73. Calviello G, Serini S, Piccioni E, Pessina G. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer (2009) 61(3):287-301. doi:10.1080/01635580802582777
74. van der Meij BS, Langius JA, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr (2010) 140(10):1774-80. doi:10.3945/jn.110.121202
75. Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M, et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr (2012) 108(2):327-33. doi:10.1017/S0007114511005551
76. Xue H, Le Roy S, Sawyer MB, Field CJ, Dieleman LA, Baracos VE. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. Br J Nutr (2009) 102(3):434-42. doi:10.1017/S0007114508199482
77. Silva Jde A, Trindade EB, Fabre ME, Menegotto VM, Gevaerd S, Buss Zda S, et al. Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. Nutr Cancer (2012) 64(2):267-73. doi:10.1080/01635581.2012.643133
78. Mocellin MC, Pastore e Silva Jde A, Camargo Cde Q, Fabre ME, Gevaerd S, Naliwaiko K, et al. Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids (2013) 48(9):879-88. doi:10.1007/s11745-013-3816-0
79. Camargo Cde Q, Mocellin MC, Pastore Silva Jde A, Fabre ME, Nunes EA, Trindade EB. Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutr Cancer (2016) 68(1):70-6. doi:10.1080/01635581.2016.1115097
80. Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, et al. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut (2014) 63(11):1760-8. doi:10.1136/gutjnl-2013-306445
81. Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer (2014) 14(10):683-91. doi:10.1038/nrc3798
82. De Carlo F, Witte TR, Hardman WE, Claudio PP. Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS One (2013) 8(7):e69760. doi:10.1371/journal.pone.0069760
83. Yang T, Fang S, Zhang HX, Xu LX, Zhang ZQ, Yuan KT, et al. N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro. J Nutr Biochem (2013) 24(5):744-53. doi:10.1016/j.jnutbio.2012.03.023